|
09-2025
|
Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
Women's Ischemia Trial to Reduce Events in Non-Obstructive CAD (WARRIOR)
|
|
08-2025
|
Alcohol-Associated Syndemic and Microbiome Evaluation and Targeted Treatment in Persons Living with HIV
Alcohol-Associated Syndemic and Microbiome Evaluation and Targeted Treatment in Persons Living with HIV
|
|
06-2025
|
The Microvascular Aging and Eicosanoids # Women#s Evaluation of Systemic aging Tenacity (MAE-WEST) Specialized Center of Research Excellence (SCORE) on Sex Differences
The Microvascular Aging and Eicosanoids # Women#s Evaluation of Systemic aging Tenacity (MAE-WEST) Specialized Center of Research Excellence (SCORE) on Sex Differences
|
|
05-2025
|
All-Extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function during Chemotherapy for Breast Cancer #######
All-Extremity Exercise as a Novel Strategy for Optimizing Cardiovascular Function during Chemotherapy for Breast Cancer #######
|
|
02-2025
|
Women#s Ischemia Syndrome Evaluation (WISE) # Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)
Women#s Ischemia Syndrome Evaluation (WISE) # Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)
|
|
02-2025
|
Women#s Ischemia Syndrome Evaluation (WISE) # Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)
Women#s Ischemia Syndrome Evaluation (WISE) # Mechanisms of Coronary Microvascular Dysfunction Leading to Pre-Heart Failure with Preserved Ejection Fraction (HFpEF)
|
|
05-2024
|
Sex Differences in Chronic and Acute Vascular Responses to Aerobic Exercise in Older Adults
Sex Differences in Chronic and Acute Vascular Responses to Aerobic Exercise in Older Adults
|
|
02-2024
|
Microvascular Disease Burden and Cerebral Small Vessel Disease: Relations to Neurocognition
Microvascular Disease Burden and Cerebral Small Vessel Disease: Relations to Neurocognition
|
|
06-2023
|
Risk of adverse cardiovascular events in breast cancer patients receiving systemic adjuvant therapy: impact of comorbidity burden
Risk of adverse cardiovascular events in breast cancer patients receiving systemic adjuvant therapy: impact of comorbidity burden
|
|
06-2023
|
Advancing Personalized Hypertension Care through Big Data Science
Advancing Personalized Hypertension Care through Big Data Science
|
|
10-2022
|
Preventing the Calcium Channel Blocker # Lower Extremity Edema # Loop Diuretic Prescribing Cascade in Older Adults
Preventing the Calcium Channel Blocker # Lower Extremity Edema # Loop Diuretic Prescribing Cascade in Older Adults
|
|
08-2022
|
Enhancing evidence generation by linking randomized clinical trials (RCTs) to real world data (RWD)
Enhancing evidence generation by linking randomized clinical trials (RCTs) to real world data (RWD)
|
|
06-2022
|
Neural mechanisms of host-microbiota interaction in hypertension: a potential for bio-electronic medicine
Neural mechanisms of host-microbiota interaction in hypertension: a potential for bio-electronic medicine
|
|
01-2022
|
Vascular Smooth Muscle Lysyl Oxidase Mediated Increase in Vessel Stiffness and its Effect on Rho-Kinase Mechanosensors: A Novel Mechanism of Atherosclerosis in Chronic Kidney Disease?
Vascular Smooth Muscle Lysyl Oxidase Mediated Increase in Vessel Stiffness and its Effect on Rho-Kinase Mechanosensors: A Novel Mechanism of Atherosclerosis in Chronic Kidney Disease?
|
|
09-2021
|
Brain-Gut Microbiome-Immune Axis in Hypertension
Brain-Gut Microbiome-Immune Axis in Hypertension
|
|
06-2021
|
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE)
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE)
|
|
06-2021
|
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE)
Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE)
|
|
05-2021
|
OR-DRPD-ROF2018: Perfusable Magnetic Cryoprotecting Agents for Heart Biobanking
OR-DRPD-ROF2018: Perfusable Magnetic Cryoprotecting Agents for Heart Biobanking
|
|
08-2020
|
CCTRN-2 Time, Late Time, and Focus
CCTRN-2 Time, Late Time, and Focus
|
|
08-2020
|
CCTRN-2 Time, Late Time, and Focus
CCTRN-2 Time, Late Time, and Focus
|
|
08-2020
|
UFRCC for Cardiovascular Cell Therapy Research Network
UFRCC for Cardiovascular Cell Therapy Research Network
|
|
08-2020
|
Treatment with Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina and Myocardial Ischemia
Treatment with Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina and Myocardial Ischemia
|
|
08-2020
|
Treatment with Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina and Myocardial Ischemia
Treatment with Ranolazine in Microvascular Coronary Dysfunction (MCD): Impact on Angina and Myocardial Ischemia
|
|
09-2019
|
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)
|
|
09-2019
|
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated heart failure (INVESTED)
|
|
05-2019
|
Angiotensin and neuroimmune activation in hypertension
Angiotensin and neuroimmune activation in hypertension
|
|
03-2019
|
OneFlorida Clinical Research Consortium Phase II
OneFlorida Clinical Research Consortium Phase II
|
|
12-2018
|
Adipose-Derived Regenerative Cells in the Treatment of Patients with Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization
Adipose-Derived Regenerative Cells in the Treatment of Patients with Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization
|
|
12-2018
|
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
|
|
11-2018
|
The LIFE Study
The LIFE Study
|
|
08-2018
|
STOP HEART DISEASE
STOP HEART DISEASE
|
|
03-2018
|
A Phase 2 prospective, randomized, double-blind, sham-controlled, parallel-group, multi-center trial of AMI MultiStem? in subjects with non-ST elevation acute myocardial infarction (NSTEMI)
A Phase 2 prospective, randomized, double-blind, sham-controlled, parallel-group, multi-center trial of AMI MultiStem? in subjects with non-ST elevation acute myocardial infarction (NSTEMI)
|
|
07-2017
|
Pharmacogenomic Evaluation of Antihypertensive Responses.
Pharmacogenomic Evaluation of Antihypertensive Responses.
|
|
05-2017
|
A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction
A Prospective Randomized Double Blinded Placebo Controlled Phase II Trial of Intra-coronary Infusion of AMR-001, a Bone Marrow Derived Autologous CD34+ Selected Cell Product, in Patients with Acute Myocardial Infarction
|
|
03-2017
|
A Double-blind, Randomized, Sham#procedure#controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP#41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic
A Double-blind, Randomized, Sham#procedure#controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP#41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic
|
|
03-2017
|
A Double-blind, Randomized, Sham#procedure#controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP#41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic
A Double-blind, Randomized, Sham#procedure#controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP#41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic
|
|
03-2017
|
A Double-blind, Randomized, Sham#procedure#controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP#41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic
A Double-blind, Randomized, Sham#procedure#controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (CEP#41750) in Patients with Chronic Heart Failure Due to Left Ventricular Systolic Dysfunction of Either Ischemic
|
|
12-2016
|
ALLSTAR (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration)
ALLSTAR (ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration)
|
|
09-2016
|
A STUDY OF QUINAPRIL IN WOMEN WITH CHEST PAIN, CORONARY
A STUDY OF QUINAPRIL IN WOMEN WITH CHEST PAIN, CORONARY
|
|
08-2016
|
01081606
01081606
|
|
06-2016
|
Chemometric Observations of Lipid Core Containing Plaques of Interest in Native Coronary Arteries (COLOR) Registry
Chemometric Observations of Lipid Core Containing Plaques of Interest in Native Coronary Arteries (COLOR) Registry
|
|
05-2016
|
Characterization of Adipose Derived Regenerative Cells (ADRCs) from excess tissue and cells designated for discard from patients with chronic heart disease
Characterization of Adipose Derived Regenerative Cells (ADRCs) from excess tissue and cells designated for discard from patients with chronic heart disease
|
|
04-2016
|
Optimizing Rural Health Clinic Infrastructure to Maximize BP Control (OPTI-BP)
Optimizing Rural Health Clinic Infrastructure to Maximize BP Control (OPTI-BP)
|
|
03-2016
|
A prospective, randomized, double-blinded, active-control and unblindedstandard of care (SOC) controlled study to determine the efficacy and safety oftargeted intramyocardial delivery of autologous CD34+ cells (Auto-CD34+cells) for increasing exerc
A prospective, randomized, double-blinded, active-control and unblindedstandard of care (SOC) controlled study to determine the efficacy and safety oftargeted intramyocardial delivery of autologous CD34+ cells (Auto-CD34+cells) for increasing exerc
|
|
03-2016
|
A prospective, randomized, double-blinded, active-control and unblindedstandard of care (SOC) controlled study to determine the efficacy and safety oftargeted intramyocardial delivery of autologous CD34+ cells (Auto-CD34+cells) for increasing exerc
A prospective, randomized, double-blinded, active-control and unblindedstandard of care (SOC) controlled study to determine the efficacy and safety oftargeted intramyocardial delivery of autologous CD34+ cells (Auto-CD34+cells) for increasing exerc
|
|
02-2016
|
SOLID-TIMI
SOLID-TIMI
|
|
10-2015
|
PRESERVATION 1
PRESERVATION 1
|
|
08-2015
|
WISE CMR
WISE CMR
|
|
02-2015
|
ATHENA II
ATHENA II
|
|
12-2014
|
T3SS-Mediated Cardiomyocyte Engineering
T3SS-Mediated Cardiomyocyte Engineering
|
|
12-2014
|
STABILITY
STABILITY
|
|
12-2014
|
CTSN/CCTRN LVAD
CTSN/CCTRN LVAD
|
|
03-2014
|
Abbott Professional Services Agreement
Abbott Professional Services Agreement
|
|
07-2013
|
Ancillary Functional Studies for the CCTRN
Ancillary Functional Studies for the CCTRN
|
|
12-2012
|
PRECISION
PRECISION
|
|
10-2012
|
WISE ACE
WISE ACE
|
|
02-2012
|
CCTRN Supplement
CCTRN Supplement
|
|
02-2012
|
CCTRN AMI TIME LATE
CCTRN AMI TIME LATE
|
|
02-2012
|
UFCC for Cardiovascular Cell Therapy Research Network
UFCC for Cardiovascular Cell Therapy Research Network
|
|
08-2011
|
LIFE Study - Lifestyle Interventions for the Elderly - S
LIFE Study - Lifestyle Interventions for the Elderly - S
|
|
06-2011
|
Women s Ischemia Syndrom Evalaution (WISE) Coronary Vasc
Women s Ischemia Syndrom Evalaution (WISE) Coronary Vasc
|
|
06-2011
|
RESIDUAL CONTINUING MEDICAL EDUCATION
RESIDUAL CONTINUING MEDICAL EDUCATION
|
|
06-2011
|
MISCELLANEOUS RESIDUAL
MISCELLANEOUS RESIDUAL
|
|
05-2011
|
BAXTER 34976
BAXTER 34976
|
|
07-2010
|
MARVEL
MARVEL
|
|
07-2010
|
WOMEN S ISCHEMIA SYNDROME EVALUATION (WISE) SUB-STUDY-5
WOMEN S ISCHEMIA SYNDROME EVALUATION (WISE) SUB-STUDY-5
|
|
06-2010
|
WISE Pathophysiology
WISE Pathophysiology
|
|
04-2010
|
AWARE
AWARE
|
|
12-2009
|
BAXTER CLI
BAXTER CLI
|
|
09-2009
|
A MULTI-CTR,RNDMZD,DBL-BL,PLCB-CNTRL STDY TO EVAL THE EF
A MULTI-CTR,RNDMZD,DBL-BL,PLCB-CNTRL STDY TO EVAL THE EF
|
|
08-2009
|
HYPERTENSION PHARMACOGENETICS
HYPERTENSION PHARMACOGENETICS
|
|
07-2009
|
BAXTER 24779
BAXTER 24779
|
|
06-2009
|
FENOFIBRIC ACID M05-749
FENOFIBRIC ACID M05-749
|
|
06-2009
|
FENOFIBRIC ACID M05-758
FENOFIBRIC ACID M05-758
|
|
05-2009
|
WISE II
WISE II
|
|
01-2009
|
VIRON Serp-1-01-002
VIRON Serp-1-01-002
|
|
11-2007
|
CETP-OP
CETP-OP
|
|
12-2006
|
ABBOTT INVEST
ABBOTT INVEST
|
|
12-2006
|
THE INTERNATIONAL VERAPAMIL-TRANDOLAPRIL STUDY (INVEST)
THE INTERNATIONAL VERAPAMIL-TRANDOLAPRIL STUDY (INVEST)
|
|
12-2006
|
INVEST
INVEST
|
|
11-2006
|
Heart Disease Outcomes
Heart Disease Outcomes
|
|
10-2006
|
PILOT STDY TO DETERMINE EFFECT OF CELECOXIB 400MG and 800M
PILOT STDY TO DETERMINE EFFECT OF CELECOXIB 400MG and 800M
|
|
09-2006
|
FEMHART
FEMHART
|
|
06-2006
|
HEART DISEASE OUTCOMES:IMPACT OF GENETICS and PHARMACOGENE
HEART DISEASE OUTCOMES:IMPACT OF GENETICS and PHARMACOGENE
|
|
12-2005
|
INVEST
INVEST
|
|
08-2005
|
BETA-BLOCKER PHARMACOGENETICS IN ETHNIC POPULATION: A SU
BETA-BLOCKER PHARMACOGENETICS IN ETHNIC POPULATION: A SU
|
|
06-2005
|
DIVISION RESIDUAL ACCOUNT
DIVISION RESIDUAL ACCOUNT
|
|
06-2005
|
HEART DISEASE OUTCOMES:IMPACT OF GENETICS and PHARMACOGENE
HEART DISEASE OUTCOMES:IMPACT OF GENETICS and PHARMACOGENE
|
|
05-2005
|
RENIN ANGIOSTENSIN FOR CORONARY MICROVASCULAR DYSFUNCTIO
RENIN ANGIOSTENSIN FOR CORONARY MICROVASCULAR DYSFUNCTIO
|
|
06-2004
|
TNT
TNT
|
|
09-2003
|
LOVENOX IN ATRIAL FIBRILLATION
LOVENOX IN ATRIAL FIBRILLATION
|
|
07-2003
|
RNDMZED,DBL-BLND,PLACEBO-CNTRLLED,PARALELL GROUP,COMPARA
RNDMZED,DBL-BLND,PLACEBO-CNTRLLED,PARALELL GROUP,COMPARA
|
|
12-2002
|
GENETICS DATABASE OF INVEST POPULATION; GENETICS AND
GENETICS DATABASE OF INVEST POPULATION; GENETICS AND
|
|
06-2002
|
STUDY OF THE CHRONIC ADMINISTRATION OF OPC-8212
STUDY OF THE CHRONIC ADMINISTRATION OF OPC-8212
|
|
05-2002
|
ALTERED RENIN ANGIOSTENSIN SYSTEM AS MECHANISM FOR CORON
ALTERED RENIN ANGIOSTENSIN SYSTEM AS MECHANISM FOR CORON
|
|
02-2002
|
CARISA: (CTV-3033) A DBL-BL RANDOMIZED STRATIFIED PLCB-C
CARISA: (CTV-3033) A DBL-BL RANDOMIZED STRATIFIED PLCB-C
|
|
01-2002
|
A PHASE III DBL-BL EFFIC and SAF STDY OF SCH 58235 (10MG)
A PHASE III DBL-BL EFFIC and SAF STDY OF SCH 58235 (10MG)
|
|
04-2001
|
XANADU
XANADU
|
|
02-2001
|
(QUASAR) A 16 WK, DBL-BL, PLCB-CNTRL, PRLEL GROUP STUDY
(QUASAR) A 16 WK, DBL-BL, PLCB-CNTRL, PRLEL GROUP STUDY
|
|
06-2000
|
NATRECOR VS DOBUTAMINE
NATRECOR VS DOBUTAMINE
|
|
06-2000
|
MYOCARDIAL ISCHEMIA REDUCTION WITH AGGRESSIVE CHOLESTERO
MYOCARDIAL ISCHEMIA REDUCTION WITH AGGRESSIVE CHOLESTERO
|
|
06-2000
|
RANOLAZINE CVT 3031
RANOLAZINE CVT 3031
|
|
06-2000
|
OTSUKA 96-201
OTSUKA 96-201
|
|
06-2000
|
IMPRESS TRIAL
IMPRESS TRIAL
|
|
06-2000
|
BMS 013
BMS 013
|
|
06-2000
|
STUDY OF CHRONIC EFFICACY and SAFETY OF OPC-18790 FOR THE
STUDY OF CHRONIC EFFICACY and SAFETY OF OPC-18790 FOR THE
|
|
06-2000
|
STUDY OF INTERMITTENT INTRAVENOUS MILRINONE THERAPY IN T
STUDY OF INTERMITTENT INTRAVENOUS MILRINONE THERAPY IN T
|
|
06-2000
|
OTSUKA 202
OTSUKA 202
|
|
06-2000
|
STARS
STARS
|
|
06-2000
|
NATRECOR
NATRECOR
|
|
06-2000
|
SANOFI ACT 2401
SANOFI ACT 2401
|
|
06-2000
|
ZOPLORESTAT
ZOPLORESTAT
|
|
06-2000
|
VEST
VEST
|
|
06-2000
|
ADOSE-RANGING OF FDP ON HEMODYNAMICS IN PATIENTS WITH
ADOSE-RANGING OF FDP ON HEMODYNAMICS IN PATIENTS WITH
|
|
06-2000
|
THE EFFECT OF RO 40-5967 ON ALL CUASES OF MORTALITY IN C
THE EFFECT OF RO 40-5967 ON ALL CUASES OF MORTALITY IN C
|
|
03-2000
|
RANOLAZINE CVT 3032
RANOLAZINE CVT 3032
|
|
02-2000
|
A TRIAL TO INVESTIGATE THE COMPARATIVE EFFICACY and SAFETY
A TRIAL TO INVESTIGATE THE COMPARATIVE EFFICACY and SAFETY
|
|
01-2000
|
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL
BETA BLOCKER EVALUATION OF SURVIVAL TRIAL
|
|
10-1999
|
EVALUATION OF THE EFFICACY and SAFETY OF OPC-18790 IN THE
EVALUATION OF THE EFFICACY and SAFETY OF OPC-18790 IN THE
|
|
08-1999
|
ACIP 001
ACIP 001
|
|
07-1999
|
GENSIA
GENSIA
|
|
06-1999
|
NOVA - SALARY FUNDS
NOVA - SALARY FUNDS
|
|
06-1999
|
STUDY COMPARING AGGRESSIVE LIPID LOWERING WITH ATORVASTA
STUDY COMPARING AGGRESSIVE LIPID LOWERING WITH ATORVASTA
|
|
06-1999
|
TREND
TREND
|
|
06-1999
|
SCAI BRACCO
SCAI BRACCO
|
|
06-1999
|
STUDY TO INVESTIGATE THE SAFETY and CLINICAL OF EFFICACY O
STUDY TO INVESTIGATE THE SAFETY and CLINICAL OF EFFICACY O
|
|
06-1999
|
BMS EXERCISE
BMS EXERCISE
|
|
05-1999
|
STUDY OF ESCALATING MULTIPLE DOSES OF DMP754 IN PATIENTS
STUDY OF ESCALATING MULTIPLE DOSES OF DMP754 IN PATIENTS
|
|
12-1998
|
BMS IBERSARTAN
BMS IBERSARTAN
|
|
12-1998
|
COMPARISON OF THE ANTISCHEMIC ACTIVITY OF ORAL MS 180291
COMPARISON OF THE ANTISCHEMIC ACTIVITY OF ORAL MS 180291
|
|
10-1998
|
EVALUATE THE EFFECT OF QUINAPRIL IN REDUCING ISCHEMIC
EVALUATE THE EFFECT OF QUINAPRIL IN REDUCING ISCHEMIC
|
|
06-1998
|
LONG TERM HEMODYNAMIC EFFECTS.....METALLOPROTEASE INHIBI
LONG TERM HEMODYNAMIC EFFECTS.....METALLOPROTEASE INHIBI
|
|
06-1998
|
PLACEBO CONTROLLED SINGLE DOSE CROSS-OVER TRIAL TO EVALU
PLACEBO CONTROLLED SINGLE DOSE CROSS-OVER TRIAL TO EVALU
|
|
06-1998
|
EVALUATE THE SAFETY and HEMODYNAMIC EFFECTS OF SINGLE ORAL
EVALUATE THE SAFETY and HEMODYNAMIC EFFECTS OF SINGLE ORAL
|
|
06-1998
|
SIGMA TAU SALARY FUNDS
SIGMA TAU SALARY FUNDS
|
|
06-1998
|
BIOGEN
BIOGEN
|
|
06-1998
|
NTG
NTG
|
|
06-1998
|
RANOLAZINE
RANOLAZINE
|
|
06-1998
|
PROVISION OF SALARY FUNDS
PROVISION OF SALARY FUNDS
|
|
08-1997
|
EVALUATION OF ISCHEMIC HEART DISEASE IN WOMEN - CLINICA
EVALUATION OF ISCHEMIC HEART DISEASE IN WOMEN - CLINICA
|
